Animal studies support that theory. GLP-1 drugs reduce inflammation in the brain and interfere with reward pathways linked to ...

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

An Ozempic-like drug prescribed for diabetes has been found to reduce the frequency of debilitating migraine. Researchers say ...

Danish drugmaker Novo Nordisk is working to bring its blockbuster drug Ozempic to India “as soon as possible", Dr Yan Cai, ...

India is among the top two countries in terms of type 2 diabetes cases and third in terms of obesity; hence, the need for ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least. Yet, the ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

A drug that outperforms placebo in helping people to lose weight is one of a growing number of next-generation obesity drugs being produced in China. Nowadays, China is emerging as important innovator ...